Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ambu A/S (AMBU-B.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
77.00-1.18 (-1.51%)
At close: 04:59PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close78.18
Open78.20
Bid76.86 x 0
Ask76.94 x 0
Day's Range76.38 - 80.26
52 Week Range65.00 - 225.70
Volume814,312
Avg. Volume1,824,714
Market Cap21.69B
Beta (5Y Monthly)0.51
PE Ratio (TTM)77.00
EPS (TTM)1.00
Earnings DateN/A
Forward Dividend & Yield0.29 (0.40%)
Ex-Dividend DateDec 15, 2021
1y Target Est110.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AMBU-B.CO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction program. Full-year 2021/22 guidance revised

      Preliminary Q3 organic revenue growth was 8%. Visualization organic growth was 0%, Anaesthesia organic growth was 14%, and Patient Monitoring & Diagnostics (PMD) organic growth was 20%.Current trading for July, the first month of the last quarter of the financial year 2021/22, showed an organic revenue growth of 6%, significantly below expectations.Decision to launch a cost reduction program expected to result in an annualised savings of DKK 250m from the financial year 2022/23. One-off expenses

    • GlobeNewswire

      Britt Meelby Jensen appointed new CEO of Ambu

      The Board of Directors of Ambu A/S has appointed Britt Meelby Jensen as new Chief Executive Officer (CEO). Britt Meelby Jensen has served as board member of Ambu since 2019, a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will leave Ambu after three years and support the new CEO in the transition as needed. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on

    • GlobeNewswire

      Interim report for Q2 2021/22 and the half-year

      For Q2, Ambu posted organic revenue growth of 8% with reported growth of 12%. The macroeconomic headwinds with inflation and continued congestion of the global supply chain are further increasing our costs of production and distribution. We also expect a return of elective procedures to above 2019 levels, but with lower benefit from pent-up demand due to hospital labour shortages. With 70% of our revenue coming from elective procedures, we adjust our financial outlook downward to organic growth

    Advertisement
    Advertisement